Drug delivery methods have a profound impact on retinal therapy efficacy and patient adherence—with intravitreal injections, the current standard for anti-VEGF drugs, requiring frequent in-clinic visits. Sustained-release formulations, which deliver medication slowly over weeks or months, are emerging as a game-changer, reducing treatment burden and improving compliance. This innovation is not only enhancing patient experience but also driving demand for advanced retinal drugs, reshaping the market’s competitive landscape.

Intravitreal injections, while effective, pose challenges. Patients with wet AMD often need monthly injections, leading to missed doses and treatment gaps. Sustained-release devices, such as EyeNetra’s micro-implantable sustained release (ISR) system, aim to address this by releasing drugs like bevacizumab or aflibercept gradually. These devices, implanted during a single procedure, can maintain therapeutic drug levels for 6–12 months, drastically reducing the need for repeat injections. Early clinical trials have shown comparable efficacy to monthly injections, with higher patient satisfaction due to fewer visits. This convenience is a key driver of market adoption, particularly among elderly patients and those with mobility issues.

Beyond implants, other sustained-release approaches are being explored. Liposomal formulations, which encapsulate drugs in lipid particles, and polymer-based microspheres, are being tested for their ability to release medication over extended periods. For example, Alcon’s phase 2 trial for a dexamethasone intravitreal implant (Ozurdex) demonstrated sustained efficacy in DR for up to 6 months, reducing injection frequency from monthly to quarterly. These innovations also lower healthcare costs by minimizing clinic visits and associated labor. Pharma companies are investing heavily in this area, with pipeline candidates targeting not just anti-VEGF drugs but also neuroprotective agents and gene therapies.

The shift toward sustained-release formulations is expected to accelerate market growth, as these products offer clear advantages over traditional injections. However, challenges like device compatibility with existing treatments, long-term safety, and regulatory approval persist. Companies must carefully balance innovation with clinical validation to gain market trust. For insights into the most promising sustained-release technologies, their market adoption potential, and competitive strategies, the sustained-release retinal drug delivery market trends and innovation report by Market Research Future provides detailed analysis, including technological comparisons, clinical trial data, and forecasts for segment growth.